Unichem, Lupin recall high blood pressure drugs from US over quality issues

The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility

Drug firms, Lupin, Cadila Healthcare
Lisinopril tablets are used to treat high blood pressure. (Representative Image)
Press Trust of India New Delhi
2 min read Last Updated : Jun 21 2020 | 1:30 PM IST

Pharma companies Unichem Laboratories and Lupin are separately recalling certain batches of drugs from the US market due to quality issues.

As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Unichem is voluntarily recalling 1,90,992 bottles of Clonodine Hydrochloride tablets, which are used to treat high blood pressure.

Unichem Pharmaceuticals (USA), the US-based arm of the company, is recalling the drug for "failed impurities/ degradation specifications".

There can be "potential migration of benzophenone at very low level into the product from container", the US health regulator noted in the report.

The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility.

ALSO READ: Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis

The USFDA has classified the action as a Class-III recall, which is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences."

Similarly, the US-based arm of Lupin is voluntarily recalling 4,224 bottles of a product in the country.

The Class-II recall is on account of "Product Mix Up: Lisinopril 10 mg tablets were found in Lisinopril 5 mg 1000-count bottle," the report said.

Lisinopril tablets are used to treat high blood pressure.

The product has been manufactured at Mumbai-based Lupin's Nagpur plant.

As per USFDA, a Class-II recall is initiated in a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Unichem LaboratoriesLupin Pharmahigh blood pressureGoaUnited StatesUSFDA

Next Story